CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
Rhea-AI Summary
CVRx (NASDAQ: CVRX), a commercial-stage medical device company focused on neuromodulation therapies for cardiovascular disease, announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, starting at 1:00 p.m. ET.
A live webcast of the presentation and a time-limited archived replay will be accessible via the company’s investor relations website at ir.cvrx.com.
Positive
- None.
Negative
- None.
News Market Reaction – CVRX
In the Jul 28 session, CVRX gained 1.43%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 23 | Earnings date notice | Neutral | -3.1% | Announced second-quarter results release and conference call scheduled for August 6 |
| Jun 09 | Leadership change | Neutral | -3.7% | CFO Jared Oasheim announced transition while successor search began |
| May 27 | Conference presentation | Neutral | -2.6% | Management scheduled presentation at Goldman Sachs healthcare conference |
| May 20 | Conference presentation | Neutral | +0.2% | Management scheduled presentation at William Blair growth stock conference |
| May 14 | Coverage policy | Positive | +10.0% | Humana issued Medicare Advantage coverage policy for Barostim therapy |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
CVRx conference and scheduling announcements were followed by mostly negative 24-hour reactions, while the coverage-policy event produced a positive reaction.
Key Terms
neuromodulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The Company's presentation will begin at 1:00 p.m. (ET).
A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
